Immunosuppressive Drugs: Cyclosporine, Tacrolimus, Sirolimus, Azathioprine, Mycophenolate Mofetil, and Corticosteroids

Lung and Heart–Lung Transplantation

Volumn , Issue , 2006, Pages 363-399

  Lu, Brandon S ^a   Garrity, Edward R ^a   Bhorade, Sangeeta M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885543955     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420019285-21     Document Type: Chapter

References (237)

1. Grover FL, Fullerton DA, Zamora MR, et al. The past, present, and future of lung transplantation. Am J Surg 1997; 173(6):523–533.
2. Trulock EP, Edwards LB, Taylor DO, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-first official adult lung and heart–lung transplant report—2004. J Heart Lung Transplant 2004; 23(7):804–815.
3. Zuckermann A, Klepetko W. Use of cyclosporine in thoracic transplantation. Transplant Proc 2004; 36(2S):331S–336S.
4. Derom F, Barbier F, Ringoir S, et al. Ten-month survival after lung homotransplantation in man. J Thorac Cardiovasc Surg 1971; 61(6):835–846.
5. Goldberg M, Lima O, Morgan E, et al. A comparison between cyclosporin A and methylprednisolone plus azathioprine on bronchial healing following canine lung autotransplantation. J Thorac Cardiovasc Surg 1983; 85(6):821–826.
6. Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 1986; 314(18):1140–1145.
7. Kahan BD. Cyclosporine. N Engl J Med 1989; 321(5):1725–1738.
8. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993; 696:9–19.
9. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13(4):136–142.
10. Parekh K, Trulock E, Patterson GA. Use of cyclosporine in lung transplantation. Transplant Proc 2004; 36(2S):318S–322S.
11. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 2004; 23:159–171.
12. El-Gamel A, Awad M, Yonan N, et al. Does cyclosporin promote the secretion of transforming growth factor-beta 1 following pulmonary transplantation? Transplant Proc 1998; 30(4):1525–1527.
13. Ahuja SS, Shrivastav S, Danielpour D, et al. Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 1995; 60(7):718–723.
14. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or highfat meals. Transplantation 1995; 59(4):505–511.
15. Reynaud-Gaubert M, Viard L, Girault D, et al. Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis. Transplant Proc 1997; 29: 2450–2453.
16. Mikhail G, Eadon H, Leaver N, et al. An investigation of the pharmacokinetics, toxicity, and clinical efficacy of Neoral cyclosporin in cystic fibrosis patients. Transplant Proc 1997; 29(1–2):599–601.
17. Kesten S, Scavuzzo M, Laurin L, et al. Conversion from standard cyclosporine to Neoral in lung transplant recipients. Transplant Proc 1998; 30:1895–1897.
18. Aziz T, El-Gamel A, Keevil B, et al. Clinical impact of Neoral in thoracic organ transplantation. Transplant Proc 1998; 30:1900–1903.
19. Zaldonis DB, Keenan RJ, Pham SM, et al. Neoral conversion in stable thoracic transplant patients leads to dose reduction. Transplant Proc 1998; 30: 1158–1159.
20. Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 1989; 11(3):246–248.
21. Takahara S, Kokado Y, Kameoka H, et al. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. Transplant Proc 1994; 26(5):2802–2806.
22. Jacksch P, Kocher A, Neuhauser P, et al. Monitoring of CyA C2 levels is predictive for AUC in lung transplant recipients. J Heart Lung Transplant 2002; 21(1):87.
23. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation 2002; 73(9):S12–S18.
24. Cantarovich M, Elstein E, de Varennes B, et al. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999; 68(12):1839–1842.
25. Poirier CD. Promise of Neoral C2, basiliximab, and everolimus in lung transplantation. Transplant Proc 2004; 36(2S):509S–513S.
26. Trull A, Steel L, Sharples L, et al. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Ther Drug Monit 1999; 21(1):17–26.
27. Dumont RJ, Partovi N, Levy RD, et al. A limited sampling strategy for cyclosporine area under the curve monitoring in lung transplant recipients. J Heart Lung Transplant 2001; 20(8):897–900.
28. Morton JM, Aboyoun CL, Malouf MA, et al. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant 2004; 23(9):1035–1039.
29. Banner NR, Yacoub MH. Cyclosporine in thoracic organ transplantation. Transplant Proc 2004; 36(2S):302S–308S.
30. Lima O, Cooper JD, Peters WJ, et al. Effects of methylprednisolone and azathioprine on bronchial healing following lung autotransplantation. J Thorac Cardiovasc Surg 1981; 82(2):211–215.
31. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 1986; 314(19):1219–1225.
32. Starzl TE, Klintmalm GB, Porter KA, et al. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med 1981; 305(5):266–269.
33. Oyer PE, Stinson EB, Jamieson SW, et al. Cyclosporine in cardiac transplantation: a 2 1/2 year follow-up. Transplant Proc 1983; 15:2546.
34. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306(10):557–564.
35. The Toronto Lung Transplant Group. Experience with single-lung transplantation for pulmonary fibrosis. J Am Med Assoc 1988; 259(12):2258–2262.
36. Corcoran TE, Smaldone GC, Dauber JH, et al. Preservation of post-transplant lung function with aerosol cyclosporin. Eur Respir J 2004; 23:378–383.
37. Iacono AT, Smaldone GC, Keenan RJ, et al. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med 1997; 155:1690–1698.
38. Iacono AT, Corcoran TE, Griffith BP, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 2004; 23:384–390.
39. Wimberley SL, Haug MT III, Shermock KM, et al. Enhanced cyclosporineitraconazole interaction with cola in lung transplant recipients. Clin Transplantation 2001; 15:116–122.
40. Roberts P, Follette D, Allen R, et al. Cyclosporine A-associated thrombotic thrombocytopenic purpura following lung transplantation. Transplant Proc 1998; 30:1512–1513.
41. Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc 2004; 36(2S):229S–233S.
42. Dussol B, Reynaud-Gaubert M, Saingra Y, et al. Acute tubular necrosis induced by high level of cyclosporine A in a lung transplant. Transplantation 2000; 70 (8):1234–1236.
43. Morales JM, Andres A, Rengel M, et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16(1):121–124.
44. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporineassociated chronic nephropathy. Kidney Int 1988; 33:590–600.
45. Zuckermann A, Ploner M, Keziban U, et al. Benefit of mycophenolate-mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation. J Heart Lung Transplant 2001; 20(2):163.
46. Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2001; 21(5):540–546.
47. Takeda Y, Miyamori I, Wu P, et al. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 1995; 26(6): 932–936.
48. Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis 1996; 27(1):151–161.
49. Ventura HO, Malik FS, Mehra MR, et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997; 12(4):375–381.
50. Wijdicks EFM, Wiesner RH, Krom RAF. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995; 45(11): 1962–1964.
51. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397:530–534.
52. Thomas DW, Newcombe RG, Osborne GR. Risk factors in the development of cyclosporine-induced gingival overgrowth. Transplantation 2000; 69(4):522–526.
53. Cecchin E, Zanello F, De Marchi S. Treatment of cyclosporine-induced gingival hypertrophy. Ann Int Med 1997; 126(5):409–410.
54. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63(12):1247–1297.
55. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18(4):336–345.
56. Jensik SC, the FK 506 Kidney Transplant Study Group. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 1998; 30(4):1216–1218.
57. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331(17):1110–1115.
58. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60:580–585.
59. Jorgensen K, Povlsen J, Madsen S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002; 17:1487–1490.
60. Keenan RJ, Dauber JH, Iacono AT, et al. Long term followup-clinical trial of tacrolimus versus cyclosporine for lung transplantation. J Heart Lung Transplant 1998; 17(1):61A.
61. Reichenspurner H, Kur F, Treede H, et al. Optimization of the immunosuppressive protocol after lung transplantation. Transplantation 1999; 68(1):67–71.
62. Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 2003; 125(4): 891–900.
63. Mulligan MS, Wood DE. Optimizing lung transplant immunosuppression: beyond calcineurin inhibition. J Thorac Cardiovasc Surg 2003; 125(4):784–786.
64. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21(3):297–310.
65. Horning NR, Lynch JP, Sundaresan SR, et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant 1998; 17(8):761–767.
66. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999; 18(5):448–455.
67. Sarahrudi K, Carretta A, Wisser W, et al. The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantation. Transpl Int 2002; 15:24–28.
68. Vitulo P, Tiberio O, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21(4):435.
69. Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127(4):1126–1132.
70. Ross DJ, Lewis MI, Kramer M, et al. FK 506 ‘rescue’ immunosuppression for obliterative bronchiolitis after lung transplantation. Chest 1997; 112(5): 1175–1179.
71. Kesten S, Chaparro C, Scavuzzo M, et al. Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant 1997; 16(9): 905–912.
72. Wiebe K, Harringer W, Franke U, et al. FK506 rescue therapy in lung transplantation. Transplant Proc 1998; 30:1508–1509.
73. Lipson DA, Palevsky HI, Kotloff RM, et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. Transplant Proc 1998; 30:1505–1507.
74. Mentzer RM Jr, Jahania MS, Lasley RD, et al. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. Transplantation 1998; 65(1):109–113.
75. Revell MP, Lewis ME, Llewellyn-Jones CG, et al. Conservation of smallairway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant 2000; 19(12):1219–1223.
76. Fieguth HG, Krueger S, Wiedenmann DE, et al. Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. Transplant Proc 2002; 34:1884.
77. Verleden GM, Dupont LJ, Van Raemdonck D, et al. Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J Heart Lung Transplant 2003; 22(8):908–913.
78. Cairn J, Yek T, Banner NR, et al. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22(1):50–57.
79. van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25(10): 707–712.
80. Jain A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation. Ann Surg 2002; 236(4):429–437.
81. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359(9308):741–746.
82. Klein IHHT, Abrahams A, van Ede T, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73(5):732–736.
83. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73(5):775–782.
84. Aguirrezabalaga J, Fernandez-Selles C, Fraguela J, et al. Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin. Transplant Proc 2002; 34(5):1551–1552.
85. Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20(5):511–517.
86. Shitrit D, Starobin D, Aravot D, et al. Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient. Transplant Proc 2003; 35:627–628.
87. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65(4): 515–523.
88. Shumway SJ, Frist WH. Immunosuppressants. In: Shumway SJ, Shumway NE, eds. Thoracic Transplantation. 1st ed. Cambridge, MA: Blackwell Science, 1995:55–66.
89. Schwartz R, Dameshek W. Drug-induced immunological tolerance. Nature 1959; 183(4676):183–184.
90. Calne RY, Murray JE. Inhibition of the rejection of renal homografts in dogs by Burroughs Wellcome 57–322. Surg Forum 1961; 12:118–120.
91. Elion GB. The purine path to chemotherapy. Biosci Rep 1989; 9(5):509–529.
92. Trotter JL, Rodey GE, Gebel HM. Azathioprine decreases suppressor T cells in patients with multiple sclerosis. N Engl J Med 1982; 306(6):365–366.
93. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4þ T lymphocytes. J Clin Invest 2003; 111(8):1133–1145.
94. Chan GLC, Erdmann GR, Gruber SA, et al. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thiogaunine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30:358–363.
95. Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of humankidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268(24):1315–1323.
96. Gleason RE, Murray JE. Report from kidney transplant registry: analysis of variables in the function of human kidney transplants. Transplantation 1967; 5(2):360–373.
97. Hoffmeyer F, Hoeper MM, Spiekerkotter E, et al. Azathioprine withdrawal in stable lung and heart/lung recipients receiving cyclosporine-based immunosuppression. Transplantation 2000; 70(3):522–525.
98. Hosenpud JD, Bennett LE, Keck BM, et al. The registry for the international society for heart and lung transplantation: seventeenth official report—2000. J Heart Lung Transplant 2000; 19(10):909–931.
99. Cummins D, Sekar M, Halil O, et al. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996; 61(11):1661–1662.
100. Havrda DE, Rathbun S, Scheid D. A case report of warfarin resistance due to azathioprine and review of the literature. Pharmacotherapy 2001; 21(3):355–357.
101. King JO, Laver MC, Fairley KF. Sensitivity to azathioprine. Med J Aust 1972; 2:939–941.
102. Farthing MJ, Coxon AY, Sheaff PC. Polyneuritis associated with azathioprine sensitivity reaction. Br Med J 1980; 280(6211):367.
103. Pollack R, Nishikawa RA, Mozes MF, et al. Azathioprine-induced leukopenia— clinical significance in renal transplantation. J Surg Res 1980; 29(3): 258–264.
104. Banner NR, Lyster H. Pharmacological immunosuppression. In: Banner NR, Polak JM, Yacoub M, eds. Lung Transplantation. 1st ed. Cambridge, United Kingdom: Cambridge University Press, 2003:205–242.
105. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341:1151.
106. McLeod HL, Lin JS, Scott EP, et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55(1): 15–20.
107. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129(9):716–718.
108. Sparberg M, Simon N, Del Greco F. Intrahepatic cholestasis due to azathioprine. Gastroenterology 1969; 57(4):439–441.
109. Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986; 104(5):651–655.
110. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323(25):1767–1769.
111. Taylor AEM, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Dermatol Venerol 1992; 72:115–119.
112. Lennard L, Thomas S, Harrington CI, et al. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985; 113:723–729.
113. Lipsky JJ. Mycophenolate mofetil. Lancet 1996; 348(9038):1357–1359.
114. Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999; 10:1366–1380.
115. Blaheta RA, Leckel K, Wittig B, et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl Immunol 1998; 6(4):251–259.
116. Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77(2):275–280.
117. Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7(2):161–166.
118. Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharm 1996; 36(4):315–324.
119. Devyatko E, Ploner M, Zuckermann A, et al. Value of mycophenolic acid trough level monitoring after lung transplantation. Transplant Proc 2002; 34: 1881–1883.
120. Brunet M, Martorell J, Oppenheimer F, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 2000; 13(Suppl 1): S301–S305.
121. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60(3): 225–232.
122. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61(7):1029–1037.
123. EuropeanMycophenolateMofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345:1321–1325.
124. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66(4):507–515.
125. Squifflet J-P, Vanrenterghem Y, van Hooff JP, et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34:1584–1586.
126. Ross DJ, Waters PF, Levine M, et al. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 1998; 17(8):768–774.
127. O’Hair DP, Cantu E, McGregor C, et al. Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant 1998; 17(9):864–868.
128. Zuckermann A, Klepetko W, Birsan T, et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 1999; 18(5):432–440.
129. Bhorade SM, Jordan A, Villanueva J, et al. Comparison of three tacrolimusbased immunosuppressive regimens in lung transplantation. Am J Transplant 2003; 3:1570–1575.
130. Palmer SM, Baz MA, Sanders L, et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001; 71(12):1772–1776.
131. Glanville AR, Corris PA, McNeil KD, et al. Mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantation for the prevention of bronchiolitis obliterans syndrome (BOS): results of a 3 year international randomised trial. J Heart Lung Transplant 2003; 22(1S):S207.
132. Speich R, Boehler A, Thurnheer R, et al. Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dosage. Transplantation 1997; 64(3):533–535.
133. Whyte RI, Rossi SJ, Mulligan MS, et al. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg 1997; 64:945–948.
134. Zuckermann A, Birsan T, Thaghavi S, et al. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. Transplant Proc 1999; 31:1160–1161.
135. http://www.utdol.com/application/topic.asp?file¼drug_l_z/173237&type-¼A&selectedTitle¼2~53. (Accessed February 2005.).
136. Gerbase MW, Fathi M, Spiliopoulos A, et al. Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant 2003; 22(5):587–590.
137. Vidal E, Cantarell C, Capdevila L, et al. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. Pharmacol Toxicol 2000 87:182–184.
138. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17:200–205.
139. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004; 18: 485–492.
140. Garrigue V, Canet S, Dereure O, et al. Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication? Transplantation 2001; 72(5):968–969.
141. Apostolou T, Tsagalis G, Koutroubas G, et al. Mycophenolate mofetil and oral ulcerations. Transplantation 2004; 77(12):1911–1912.
142. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001; 24(9):645–663.
143. Puig JM, Fernandez-Crespo P, Lloveras J, et al. Risk factors that influence the incidence and severity of MMF adverse events in renal transplant patients: relationship with corticosteroid dosage, renal function, sex, and patient age. Transplant Proc 1999; 31:2270–2271.
144. Mohsin N, Jha A, Kallankara S, et al. Rapid resolution of mycophenolate mofetil associated diarrhea with a small dose of octreotide: a case report. Transplant Proc 2003; 35:2754.
145. Engelen W, Verpooten GA, Van der Planken M, et al. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol 2003; 60(2):119–124.
146. Bernabeu-Wittel M, Naranjo M, Cisneros JM, et al. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression. Eur J Clin Microbiol Infect Dis 2002; 21:173–180.
147. Munoz MA, Andres A, Gallego R, et al. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation. Transplant Proc 2002; 34:97.
148. Sarmiento JM, Dockrell DH, Schwab TR, et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14:136–138.
149. Rose ML, Smith J, Dureau G, et al. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21(2):282–285.
150. Zmonarski SC, Boratynska M, Madziarska K, et al. Mycophenolate mofetil severely depressed antibody response to CMV infection in early posttransplant period. Transplant Proc 2003; 35:2205–2206.
151. Guerard A, Rabodonirina M, Cotte L, et al. Intestinal microsporidiosis occurring in two renal transplant recipients treated with mycophenolate mofetil. Transplantation 1999; 68(5):699–701.
152. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35(1):53–61.
153. Gross DC, Sasaki TM, Buick MK, et al. Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation 1997; 64(11):1607–1609.
154. Shrestha NK, Mossad SB, Braun W. Pneumonitis associated with the use of mycophenolate mofetil. Transplantation 2003; 75(10):1762.
155. Le Ray C, Coulomb A, Elefant E, et al. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 2004; 103(5):1091–1094.
156. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation, and characterization. J Antibiot 1975; 28(10):727–732.
157. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 359(6483):756–758.
158. Feuerstein N, Firestein R, Aiyar N, et al. Late induction of CREB/ATF binding and a concomitant increase in cAMP levels in T and B lymphocytes stimulated via the antigen receptor. J Immunol 1996; 156:4582–4593.
159. Jefferies HBJ, Reinhard C, Kozma SC, et al. Rapamycin selectively represses translation of the ‘‘polypyrimidine tract’’ mRNA family. Proc Natl Acad Sci USA 1994; 91:4441–4445.
160. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277(5322):99–101.
161. Lai JH, Tan TH. CD28 signaling causes a sustained down-regulation of IkBa which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994; 269(48):30077–30080.
162. Flanagan WM, Crabtree GR. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition. Ann N Y Acad Sci 1993; 696:31–37.
163. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(Suppl 3A):7S–14S.
164. Marx S, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76(3): 412–417.
165. Nair RV, Huang X, Shorthourse R, et al. Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997; 29:614–615
166. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37(5):405–415.
167. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72(7):1181–1193.
168. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356:194–202.
169. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71(2):271–280.
170. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75(9):1437–1443.
171. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004; 23(5):632–638.
172. Bhorade SM, Ahya V, Kotloff R, et al. Comparison of sirolimus versus azathioprine in a tacrolimus based immunosuppressive regimen in lung transplantation. J Heart Lung Transplant 2004; 23(2S):S113.
173. Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22(2):169–176.
174. Ussetti P, Laporta R, de Pablo A, et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc 2003; 35:1974–1977.
175. Kaplan B, Meier-Kriesche H-U, Napoli KL, et al. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998; 63:48–53.
176. Napoli KL, Wang ME, Stepkowski SM, et al. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 1998; 20(2): 123–133.
177. McAlister VC, Mahalati K, Peltekian KM, et al. Aclinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24(3):346–350.
178. Holt DW, Ostraat O, Grinyo JM, et al. MMF may be given at lower doses when used in association with sirolimus in renal transplant recipients. Am J Transplant 2001; 1(Suppl 1):247.
179. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12:1059–1071.
180. Shihab FS; Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65(4):1262–1271.
181. Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75(6):772–780.
182. Groth CG, Brattstrom C, Claesson K, et al. New trials in transplantation: how to exploit the potential of sirolimus in clinical transplantation. Transplant Proc 1998; 30:4064–4065.
183. Langer RM, Van Buren CT, Katz SM, et al. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine A sirolimus combination. Transplant Proc 2001; 33:3236–3237.
184. Rampino T, Marasa M, Malvezzi PM, et al. Platelet-independent defect in hemostasis associated with sirolimus use. Transplant Proc 2004; 36:700–702.
185. Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35(Suppl 3A):143S–150S.
186. van Gelder T, ter Meulen CG, Hene R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75(6):788–791.
187. Pham P-TT, Pham P-CT, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77(8):1215–1220.
188. McWilliams TJ, Levvey BJ, Russell PA, et al. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003; 22(2):210–213.
189. Billingham RE, Krohn PL, Medawar PB. Effect of cortisone on survival of skin homografts in rabbits. Br Med J 1951; 1:1157–1163.
190. Billingham RE, Krohn PL, Medawar PB. Effect of locally applied cortisone acetate on survival of skin homografts in rabbits. Br Med J 1951; 2:1049– 1053.
191. Goodwin WE, Kaufman JJ, Mims MM, et al. Human renal transplantation. I, Clinical experiences with six cases of renal homotransplantation. J Urol 1963; 89(1):13–24.
192. Van LaethemF, Baus E, Andris F, et al.A novel aspect of the anti-inflammatory actions of glucocorticoids: inhibition of proximal steps of signaling cascades in lymphocytes. Cell Mol Life Sci 2001; 58:1599–1606.
193. Barnes PJ, Karin M. Nuclear factor-kB—a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15):1066–1071.
194. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270(5234):283–286.
195. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NK-kappa B activity through induction of I kappa B synthesis. Science 1995; 270(5234):286–290.
196. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 1982; 129(5):1803–1805.
197. Northrop JP, Crabtree GR, Nattila PS. Negative regulation of interleukin 2 transcription by the glucocorticoid receptor. J Exp Med 1992; 175: 1235–1245.
198. Zanker B, Walz G, Wieder KJ, et al. Evidence that glucocorticosteroids block expression of the human interleukin-6 gene by accessory cells. Transplantation 1990; 49(1):183–185.
199. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev 1982; 65:133–155.
200. Planey SL, Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 2000; 279:307–312.
201. Ferry JJ, Horvath AM, Bekersky I, et al. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol 1988; 28:81–87.
202. Pugeat MM, Dunn JF, Nisula BC. Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53(1):69–75.
203. Ballard PL, Carter JP, Graham BS, et al. A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. J Clin Endocrinol Metab 1975; 41(2):290–304.
204. Dove AM, Szefler SJ, Hill MR, et al. Altered prednisolone pharmacokinetics in patients with cystic fibrosis. J Pediatr 1992; 120(5):789–794.
205. Jeng S, Chanchairujira T, Jusko W, et al. Prednisone metabolism in recipients of kidney or liver transplants and in lung recipients receiving ketoconazole. Transplantation 2003; 75(6):792–795.
206. Hricik DE, O’Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4(6):1300–1305.
207. Smak Gregoor PJH, de Sevaux RGL, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13(5):1365–1373.
208. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11(10):1910–1917.
209. McAllister WAC, Thompson PJ, Al-Habet SM. Rifampin reduces effectiveness and bioavailability of prednisolone. Br Med J 1983; 286:923–925.
210. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 1987; 42(4):424–432.
211. Langhoff E, Madsen S, Olgaard K, et al. Clinical results and cyclosporine effect on prednisolone metabolism. Kidney Int 1984; 26:642.
212. Sarma GR, Kailasam S, Nair NGK, et al. Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob Agents Chemother 1980; 18(5):661–666.
213. Klinenberg JR, Miller F. Effect of corticosteroids on blood salicylate concentration. J Am Med Assoc 1965; 194(6):131–134.
214. Winston DJ, Ho WG, Schiffman G, et al. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983; 143:1735–1737.
215. Herron A, Dettleff G, Hixon B, et al. Influenza vaccination in patients with rheumatic diseases. J Am Med Assoc 1979; 242(1):53–56.
216. Kubiet MA, Gonzalez-Rothi RJ, Cottey R, et al. Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Chest 1996; 110(2):367–370.
217. Lahood N, Emerson SS, Kumar P, et al. Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann Allergy 1993; 70:289–294.
218. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96:115–123.
219. Berkowitz JS, David DS, Sakai S, et al. Ocular complications in renal transplant recipients. Am J Med 1973; 55:492–495.
220. Karagas MR, Cushing GL Jr, Greenberg ER, et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85(5):683–686.
221. Wolfe F, Furst D, Lane N, et al. Substantial increase in important adverse events follow low dose prednisone therapy of rheumatoid arthritis (RA). Arthritis Rheum 1995; 38:S312.
222. Jackson SHD, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci 1981; 61:381S–383S.
223. Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 1996; 50:538–542.
224. Rigotti P. Patients with high cholesterol levels benefit most from early withdrawal of corticosteroids. Transplant Proc 2002; 34:1797–1798.
225. Svenson KLG, Lithell H, Hallgren R, et al. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. Arch Intern Med 1987; 147:1917–1920.
226. Lloveras J, Senti M, Puig JM, et al. Effect of time elapsed since transplantation on lipid and lipoprotein abnormalities in renal transplant patients: role of maintenance prednisone and gender influence. Transplant Proc 1997; 29: 212–215.
227. Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy with peptic-ulcer disease. N Engl J Med 1983; 309(1):21–24.
228. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114(9):735–740.
229. Glenn F, Grafe WR Jr. Surgical complications of adrenal steroid therapy. Ann Surg 1967; 165(6):1023–1032.
230. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154:97–101.
231. Adler RA, Rosen CJ. Glucocorticoids and osteoporosis. Endocrinol Metab Clin North Am 1994; 23(3):641–654.
232. Reid IR, Heap SW. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 1990; 150: 2545–2548.
233. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995; 22:1055–1059.
234. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computer tomography. Eur J Clin Pharmacol 1983; 25: 615–620.
235. Reid IR, King AR, Alexander CJ, et al. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988; 1(8578):143–146.
236. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339(5): 292–299.
237. Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989; 30:135–139.